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Respiratory syncytial virus (RSV) is the most important 
cause of lower respiratory tract infection (LRTI) in infants 
and children and is associated with substantial morbidity in 
both inpatient and outpatient settings. Overall RSV is 
associated with 20 % of hospitalizations, 18 % of emergency 
department visits and 15 % of office visits for acute 
respiratory infections from November trough April [1]. 
Bronchiolitis hospitalizations in children younger than 2 
years old significantly increased from 3.3% in 2002 to 5.5% 
in 2007, mainly because of RSV infections in US [2]. In 
Canada, inpatient care of RSV illness costs $ 18 million (US 
dollars) yearly, accounting for 62 percent of the total cost of 
this disease [3]. The magnitude of the costs is 
understandable, since virtually all children become infected 
with RSV within two years after birth, and one percent 
requires hospitalization [4]. Recurrent wheezing following 
serious RSV associated LRTI is a common phenomenon of 
the disease that might persist until adulthood [5]. This 
Supplement of the Open Microbiology Journal focuses on 
that topic by a couple of review articles that represent a 
general clinical view. Therese Popow-Kraupp and Judith 
Aberle from the Institute of Clinical Virology of the Medical 
University of Vienna evaluate diagnostic tests for the 
detection of RSV including RSV rapid antigen detection 
tests from several specimen, nucleic acid assays and RT-
multiplex PCRs as future trends. This chapter is followed by 
a review on the epidemiology of RSV infection in preterm 
infants by Bernhard Resch and Stefan Kurath from Austria 
and Paolo Manzoni from Italy. Especially due to the 
development of the humanized monoclonal antibody 
palivizumab that provides immunoprophylaxis against RSV 
when given monthly over the RSV season in high-risk   
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infants like preterm infants this chapter represents important 
data for optimal guidance of this cost-intense prophylaxis. 
One of the leading experts world-wide on risk factors 
associated with severe RSV infection requiring 
hospitalization, Eric Simoes from Denver, USA, as the 
senior author together with authors from the Austrian RSV 
Study Group, report on patient groups at high risk for severe 
RSV disease, host-related factors increasing the severity of 
RSV disease and risk factors for the acquisition of the virus. 
At least Eric Simoes presents a short overview of risk scores 
that might be useful for the identification of late preterm 
infants at highest risk for severe RSV infection requiring 
palivizumab prophylaxis. A special population of high risk 
for severe RSV disease comprises the group of infants with 
neuromuscular impairment that is reported by Simon from 
the German RSV Study Group. The last chapter represents 
an overview of actual treatment strategies for mild and 
severe RSV LRTI done by the Austrian pulmonologist Ernst 
Eber. This Supplement of the Journal aims to put forward 
actual insights into the burden of RSV disease in young 
infants and children for both clinical and basic science 
researchers.  
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